JP2004524360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004524360A5 JP2004524360A5 JP2002577784A JP2002577784A JP2004524360A5 JP 2004524360 A5 JP2004524360 A5 JP 2004524360A5 JP 2002577784 A JP2002577784 A JP 2002577784A JP 2002577784 A JP2002577784 A JP 2002577784A JP 2004524360 A5 JP2004524360 A5 JP 2004524360A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- pyridyl
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000004076 pyridyl group Chemical group 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- -1 pyrimidyl N-oxide Chemical class 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- IDKANNMUOTVMAJ-UHFFFAOYSA-N CC(C)c1c(C)nccc1C Chemical compound CC(C)c1c(C)nccc1C IDKANNMUOTVMAJ-UHFFFAOYSA-N 0.000 description 1
- 0 Cc(cncc1*)c1N Chemical compound Cc(cncc1*)c1N 0.000 description 1
- HLTWPEDCRAMGSW-UHFFFAOYSA-N Cc1c(C)ncnc1C Chemical compound Cc1c(C)ncnc1C HLTWPEDCRAMGSW-UHFFFAOYSA-N 0.000 description 1
- UFFBMTHBGFGIHF-UHFFFAOYSA-N Cc1cccc(C)c1N Chemical compound Cc1cccc(C)c1N UFFBMTHBGFGIHF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27995001P | 2001-03-29 | 2001-03-29 | |
| PCT/US2002/009490 WO2002079157A1 (en) | 2001-03-29 | 2002-03-27 | Aryl oxime-piperazines useful as ccr5 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004524360A JP2004524360A (ja) | 2004-08-12 |
| JP2004524360A5 true JP2004524360A5 (https=) | 2009-01-22 |
| JP4303969B2 JP4303969B2 (ja) | 2009-07-29 |
Family
ID=23071025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002577784A Expired - Fee Related JP4303969B2 (ja) | 2001-03-29 | 2002-03-27 | Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6689783B2 (https=) |
| EP (1) | EP1373206B1 (https=) |
| JP (1) | JP4303969B2 (https=) |
| KR (1) | KR20030083015A (https=) |
| CN (1) | CN1253435C (https=) |
| AR (1) | AR033622A1 (https=) |
| AT (1) | ATE418542T1 (https=) |
| AU (1) | AU2002303168B2 (https=) |
| CA (1) | CA2442210C (https=) |
| DE (1) | DE60230491D1 (https=) |
| ES (1) | ES2318009T3 (https=) |
| HU (1) | HUP0400389A3 (https=) |
| IL (1) | IL157713A0 (https=) |
| MX (1) | MXPA03008801A (https=) |
| MY (1) | MY134019A (https=) |
| NZ (1) | NZ528011A (https=) |
| WO (1) | WO2002079157A1 (https=) |
| ZA (1) | ZA200307171B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7825121B2 (en) * | 1999-05-04 | 2010-11-02 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
| EP1725235B1 (en) * | 2004-02-05 | 2009-04-15 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
| BRPI0509803A (pt) | 2004-04-13 | 2007-09-18 | Incyte Corp | derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina |
| US20070215685A1 (en) * | 2005-02-03 | 2007-09-20 | Yottamark, Inc. | System and Method of Product Identification Using a URL |
| JP4769257B2 (ja) * | 2005-02-23 | 2011-09-07 | シェーリング コーポレイション | ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体 |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| KR100830003B1 (ko) * | 2006-10-31 | 2008-05-15 | 씨제이제일제당 (주) | 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법 |
| US20080173808A1 (en) * | 2007-01-18 | 2008-07-24 | Schering Corporation | Process and device for response normalized liquid chromatography nanospray ionization mass spectrometry (rnlc-nsi-ms) |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| AU2021222441A1 (en) | 2020-02-19 | 2022-09-22 | Ichilov Tech Ltd. | Improved antidepressant therapy |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4949314A (en) | 1966-08-16 | 1990-08-14 | The United States Of America As Represented By The Secretary Of The Navy | Method and means for increasing echo-ranging-search rate |
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| GB8327880D0 (en) | 1983-10-18 | 1983-11-16 | Ajinomoto Kk | Saccharomyces cerevisiae |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| IL76360A0 (en) | 1984-09-26 | 1986-01-31 | Takeda Chemical Industries Ltd | Mutual separation of proteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| NZ230045A (en) * | 1988-08-05 | 1990-11-27 | Janssen Pharmaceutica Nv | 3-piperazinylbenzazole derivatives and pharmaceutical compositions |
| US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| AU4788396A (en) | 1995-02-16 | 1996-09-04 | Children's Medical Center Corporation | Inhibition of angiogenesis using interleukin-12 |
| CA2371583C (en) * | 1999-05-04 | 2005-09-13 | Schering Corporation | Piperazine derivatives useful as ccr5 antagonists |
-
2002
- 2002-03-27 EP EP02731174A patent/EP1373206B1/en not_active Expired - Lifetime
- 2002-03-27 KR KR10-2003-7012566A patent/KR20030083015A/ko not_active Withdrawn
- 2002-03-27 MX MXPA03008801A patent/MXPA03008801A/es active IP Right Grant
- 2002-03-27 AR ARP020101139A patent/AR033622A1/es unknown
- 2002-03-27 CN CNB028076567A patent/CN1253435C/zh not_active Expired - Fee Related
- 2002-03-27 NZ NZ528011A patent/NZ528011A/en unknown
- 2002-03-27 JP JP2002577784A patent/JP4303969B2/ja not_active Expired - Fee Related
- 2002-03-27 WO PCT/US2002/009490 patent/WO2002079157A1/en not_active Ceased
- 2002-03-27 HU HU0400389A patent/HUP0400389A3/hu unknown
- 2002-03-27 ES ES02731174T patent/ES2318009T3/es not_active Expired - Lifetime
- 2002-03-27 IL IL15771302A patent/IL157713A0/xx unknown
- 2002-03-27 CA CA002442210A patent/CA2442210C/en not_active Expired - Fee Related
- 2002-03-27 AT AT02731174T patent/ATE418542T1/de not_active IP Right Cessation
- 2002-03-27 US US10/107,992 patent/US6689783B2/en not_active Expired - Fee Related
- 2002-03-27 AU AU2002303168A patent/AU2002303168B2/en not_active Expired - Fee Related
- 2002-03-27 DE DE60230491T patent/DE60230491D1/de not_active Expired - Lifetime
- 2002-03-28 MY MYPI20021141A patent/MY134019A/en unknown
-
2003
- 2003-09-12 ZA ZA200307171A patent/ZA200307171B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004524360A5 (https=) | ||
| JP2002543185A5 (https=) | ||
| RU2376287C2 (ru) | Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac | |
| JP2005511698A5 (https=) | ||
| JP2004530649A5 (https=) | ||
| CZ2003261A3 (cs) | Karbamáty a jejich použití pro výrobu farmaceutického použití | |
| GEP20084526B (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing them | |
| JP2008528467A5 (https=) | ||
| JP2008509146A5 (https=) | ||
| IL156779A0 (en) | Purine derivatives as purinergic receptor antagonists | |
| CA2545427A1 (en) | Selective kinase inhibitors | |
| CA2498051A1 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | |
| RU2005133441A (ru) | Производные имидазо-пиридина, обладающие сродством к рецептору меланокортина | |
| EP3882249A1 (en) | Deuterated derivatives of ruxolitinib | |
| JP2014520898A5 (https=) | ||
| CA2371583A1 (en) | Piperazine derivatives useful as ccr5 antagonists | |
| ME00158B (me) | Pirimidini supstituisani sulfoksiiminima kao cdk-i/ili vegf-inhibitori, njihovo dobijanje i primjena kao lijeka | |
| JP2007518822A5 (https=) | ||
| JP2007527909A5 (https=) | ||
| JP2021523241A5 (https=) | ||
| JO2676B1 (en) | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines | |
| JP2008519087A5 (https=) | ||
| JO2527B1 (en) | Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines | |
| JP2019537602A5 (https=) | ||
| JP2004507540A5 (https=) |